Result of open offer

ANGLE plc (AIM:AGL), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that, pursuant to the Open Offer announced on 5 June 2024, it has received valid applications for a total of 3,561,121 Open Offer Shares from Qualifying Shareholders.

The Open Offer raised gross proceeds of £0.5m at the Issue Price, which will be used to strengthen the Company's balance sheet. In aggregate, £9.3m of gross proceeds have been raised pursuant to the Placing, Subscription and Open Offer.

The Open Offer Shares, when issued, will be fully paid and rank pari passu in all respects with the existing ordinary shares of the Company. Application has been made for the Open Offer Shares to be admitted to trading on AIM. Admission and settlement of the Open Offer Shares is expected to take place at 8.00 a.m. on 24 June 2024.

Total voting rights

Following Second Admission, the Company will have a total of 322,641,668 ordinary shares in issue. With effect from Second Admission, this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

Unless otherwise stated, capitalised terms not otherwise defined in the text of this announcement have the same meanings ascribed to them as in the Launch Announcement published by the Company on 5 June 2024.

Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit https://angleplc.com/.